Beijing Tiantan Biological Products Co., Ltd. (SHA: 600161)

Market Cap	43.56B
Revenue (ttm)	5.23B
Net Income (ttm)	1.27B
Shares Out	1.98B
EPS (ttm)	0.64
PE Ratio	34.53
Forward PE	31.68
Dividend	0.13 (0.57%)
Ex-Dividend Date	Jun 20, 2024

Volume	12,189,926
Open	21.73
Previous Close	21.71
Day's Range	21.60 - 21.95
52-Week Range	20.17 - 27.60
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Beijing Tiantan Biological Products

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include human albumin; intravenous human immunoglobulin; tetanus human immunoglobulin; rabies patient immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; and human prothrombin complex blood products. The company was founded in 1919 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. is a subsidia...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1919
• Employees: 4,858
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2023, Beijing Tiantan Biological Products's revenue was 5.18 billion, an increase of 21.57% compared to the previous year's 4.26 billion. Earnings were 1.11 billion, an increase of 25.99%.